Default company panoramic image
Logo

Sompharmaceutical

Developing novel somatostatin analogue therapies and diagnostics for rare diseases

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Chemin des Croisettes, Epalinges, VD, Switzerland
  • Currency USD
  • Founded August 2012
  • Employees 4
  • Website sompharmaceuticals.com

Company Summary

Sompharmaceuticals S.A. a Swiss based biopharmaceutical company based at the Biopôle in Epalinges-Lausanne, Switzerland is focused on developing novel anti-tumour somatostatin analogue (SSA) peptide medicines and diagnostics for patients with rare diseases, which have unmet medical needs and major market opportunities. Contact: john.watson@sompharmaceuticals.com

Team

  • Default avatar
    Alan Harris
    Professor

    Founder , Chairman
    25 years experience in Pharma/Biotech industry
    VP Med Affairs Schering Plough-Merck; Head Endocrinology Pfizer; CMO NPS Pharma
    Led clinical development of Sandostatin™ (octreotide), the leading analogue which has 90% of the worldwide market and is worth $1.5B per year.

  • Default avatar
    Viktor Boerlin
    Dr

    Head Clinical Development
    30 years drug development experience in pharma industry
    Former Head Dept. Neuroendocrinology Sandoz/Novartis

  • Default avatar
    Hervè Porchet
    Dr

    Head Clinical Operations
    20 years drug development experience
    Therapeutic areas; reproductive medicine, endocrinology, osteoporosis, CNS, pain, hepatology, infectious diseases, pulmonary diseases, oncology and cardiovascular diseases.

Advisors

  • Default avatar
    N/A
    Lawyer
    Unconfirmed
    Default avatar
    N/A
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    None
    Unconfirmed